Samuel A. Wells

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology · 2011 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +6

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC

Helen Donis-Keller, Shenshen Dou, David Chi et al. · Human Molecular Genetics · 1993 · 1.3K citations

Life Sciences, Endocrinology, Genetics +6

Single missense mutation in the tyrosine kinasecatalytic domain of the RET protooncogene is associated with multiple endocrineneoplasia type 2B.

Katrin M. Carlson, Shuo‐Xing Dou, N J Scavarda et al. · Proceedings of the National Academy of Sciences · 1994 · 598 citations · Full text

Medicine, Genetics, Oncology +17

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Samuel A. Wells, Jessica E. Gosnell, Robert F. Gagel et al. · Journal of Clinical Oncology · 2010 · 517 citations · Full text

Medicine, Oncology, Pharmacology +17

Predictive DNA Testing and Prophylactic Thyroidectomy in Patients at Risk for Multiple Endocrine Neoplasia Type 2A

Samuel A. Wells, Doina David, Koji Toshima et al. · Annals of Surgery · 1994 · 447 citations

Life Sciences, Endocrinology, Genetics +17